Citi lowered the firm’s price target on Allogene Therapeutics (ALLO) to $4 from $8 and keeps a Buy rating on the shares. The company’s Q1 clinical update was mixed, with delayed clinical timelines for key data readouts extending the time to value realization, partially offset by strategic cash preservation efforts that extend runway into the second half of 2027, the analyst tells investors in a research note. The firm is reducing its price target to account for these timeline delays and higher clinical execution risk, Citi added.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics: Strategic Cash Management and ALPHA3 Potential Drive Buy Rating Amid Clinical Delays
- Allogene Therapeutics price target lowered to $10 from $14 at Truist
- Allogene Therapeutics price target lowered to $9 from $10 at Oppenheimer
- Allogene Therapeutics price target lowered to $9 from $12 at Baird
- Buy Rating Affirmed for Allogene Therapeutics Amid Strategic Developments and Financial Strength